

**REMARKS**

Claims 1, 3, 5, 179-184, 186, 187, 189, 192, 193, 195, 201, 204-212, 222-227, 231-233, 241, 242, 244, 245, 250, 280-299, 303 and 305-324 are currently pending in this application. Claims 1, 3, 5, 179 and 308 have been amended herein to more particularly point out and distinctly claim the invention. No new matter has been added by way of this amendment, and support can be found throughout the specification, *e.g.*, at page 8, line 21 – page 9, line 9; Table 2 (page 47 – 50); and page 67, lines 18-20. After entry of this amendment, claims 1, 3, 5, 179-184, 186, 187, 189, 192, 193, 195, 201, 204-212, 222-227, 231-233, 241, 242, 244, 245, 250, 280-299, 303 and 305-324 will be pending in this application.

The specification has been amended to replace Table 3 to correct minor typographical errors with respect to SEQ ID NOS. of the corresponding CDR sequences as provided in the Sequence Listing. In particular, SEQ ID NO:95 was inadvertently listed twice in Table 3, thereby causing following SEQ ID NOS. to be off by one. Thus, the first instance of SEQ ID NO:95 and SEQ ID NOS:96-99 were changed to SEQ ID NOS:96-100, respectively, and now correctly correspond to the sequences presented in the Sequence Listing. Also, SEQ ID NO:142, 143 and 144 have been renumbered as 143, 144 and 142, respectively, and now correctly correspond to the sequences presented in the Sequence Listing. No new matter has been added by way of this amendment.

The specification has also been amended to clarify that the A4B4 antibody used in the Examples is an A4B4 antibody distinct from the A4B4 antibody identified in Table 2. Thus, the references in the Examples section to antibody “A4B4” have been changed to “A4B4(1) (sequence not shown)” for purposes of clarification. No new matter has been added by way of this amendment.

The specification has also been amended to correct typographical errors on page 119, lines 2-4 (as amended December 5, 2001, page 31) that the framework sequences of antibodies 1X-493L2FR, H3-3F4, M3H9, Y10H6, DG, \*AFFF, 6H8, L1-7E5, L2-15B10, \*P12F2, \*P12F4, \*P11d4, \*Ale9, \*A12a6, \*A13a11, and \*A13c4 are those depicted in

Figure 2 (not Figure 1). No new matter has been added by way of this amendment, and support can be found in the originally filed specification, *e.g.*, at page 67, lines 18-20. The specification has also been amended to correct typographical errors on page 119, lines 2-4 (as amended December 5, 2001, page 31) that only SYNAGIS® (not AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4 and A8c7) has the framework of Figure 1. No new matter has been added by way of this amendment, and support can be found in the originally filed specification, *e.g.*, at page 119, lines 2-7.

The specification has also been amended to insert a substitute Sequence Listing, including new SEQ ID NOS 205 and 206, as well as corrections to SEQ ID NOS:33, 44, 46, 68, 75 and 111. No new matter has been added by way of this amendment, and support can be found in the originally filed specification. New SEQ ID NOS: 205 and 206 correspond the amino acid sequences depicted in Figures 2A and 2B, respectively. SEQ ID NO:33 (Ale9 VH domain) has been corrected at position 32 (Pro-->Ala) in the VH CDR1 to correspond with the Ale9 VH CDR1 sequence shown in Table 2. SEQ ID NO:44 (A17d4 VH domain) has been corrected at position 57 (Gly-->Asp) in VH CDR2 to correspond with the A17d4 VH CDR2 sequence shown in Table 2. SEQ ID NO:46 (A17d4 VL domain) has been corrected at position 24 (Ser-->Leu) in the VL CDR1 to correspond with the A17d4 VL CDR1 sequence shown in Table 2. SEQ ID NO:68 (A13a11 VL domain) has been corrected at position 25 (Ala-->Pro) in VL CDR1, position 28 (Ser-->Arg) in VL CDR1, and position 54 (Ala-->Ser) in VL CDR2 to correspond with the A13a11 VL CDR1 and CDR2 sequences shown in Table 2. SEQ ID NO:75 (A4B4 VL domain) has been corrected at positions 51 and 52 (Phe Phe-->Leu Leu) in the VL CDR2 to correspond with the A4B4 VL CDR2 sequence shown in Table 2. Finally, SEQ ID NO:111 (a VL CDR1) has been corrected at position 4 (Leu-->Ser) to correspond with the VL CDR1 sequence shown in Table 3.

In view of the foregoing amendments and remarks, Applicants respectfully submit that this application is in condition for immediate allowance. If the Examiner disagrees, Applicants respectfully request that the Examiner call the undersigned at the number listed below.

U.S. Serial No. 09/724,531  
RCE and Amendment dated November 21, 2006  
Page 29 of 29

A Request for Continued Examination (RCE) Transmittal is also submitted herewith, which authorizes the PTO to deduct the RCE fee of \$790 to Jones Day Deposit Account No. 50-3013. Applicants believe no other fees are due in connection with this RCE and response. However, if there are any other fees due, please charge them to Deposit Account 50-3013. If a fee is required for an extension of time under 37 C.F.R. § 1.136, such an extension is requested and the fee should be charged to our Deposit Account. Also, please charge any fees underpaid or credit any fees overpaid to the same Deposit Account.

Respectfully submitted,



Date: Nov. 21, 2006



Tamera M. Pertmer, Ph.D. (Reg. No. 47,856)  
**JONES DAY**  
12750 High Bluff Drive, Suite 300  
San Diego, CA 92130  
(858) 314-1181

*For:* Anthony M. Insogna (Reg. No. 35,203)  
**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, NY 10017-6702  
(212) 326-3939